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Reactive oxygen speciesMitochondria play a role of energy production and produce intracellular reactive oxygen species (ROS), espe-
cially superoxide anion (O2
•−) as a byproduct of energy metabolism at the same time. O2
•− is converted from
oxygen and is overproduced by excessive electron leakage from the mitochondrial respiratory chain. It is well
known that mitochondrial complexes I and III in the electron transport system are the major endogenous ROS
sources. We have previously demonstrated that mutations in complex II can result in excessive ROS (specif-
ically in SDHC: G71E in Caenorhabditis elegans, I71E in Drosophila and V69E in mouse). Moreover, this results
in premature death in C. elegans and Drosophila as well as tumorigenesis in mouse embryonic ﬁbroblast cells.
In humans, it has been reported that mutations in SDHB, SDHC or SDHD, which are the subunits of mitochon-
drial complex II, often result in inherited head and neck paragangliomas (PGLs). Recently, we established
Tet-mev-1 conditional transgenic mice using our uniquely developed Tet-On/Off system, which can induce
the mutated SDHC gene to be equally and competitively expressed compared to the endogenous wild-type
SDHC gene. These mice experienced mitochondrial respiratory chain dysfunction that resulted in oxidative
stress. The mitochondrial oxidative stress caused excessive apoptosis in several tissues leading to low-
birth-weight infants and growth retardation during neonatal developmental phase in Tet-mev-1 mice.
Tet-mev-1 mice also displayed precocious age-dependent corneal physiological changes, delayed corneal
epithelialization, decreased corneal endothelial cells, thickened Descemet's membrane and thinning of
parenchyma with corneal pathological dysfunctions such as keratitis, Fuchs' corneal dystrophy (FCD) and
probably keratoconus after the normal development and growth phase. Here, we review the relationships
between mitochondrial oxidative stress and phenomena in mev-1 animal models with mitochondrial com-
plex II SDHC mutations. This article is part of a Special Issue entitled: Respiratory complex II: Role in cellular
physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Energy metabolism in aerobic organisms is almost exclusively the
result of glycolysis, the Krebs cycle and electron transport. With respect
to electron transport, four membrane-bound complexes within mito-
chondria form the respiratory chain that sequentially transfers elec-
trons through a series of donor/acceptors, with oxygen (O2•−) as the
ﬁnal acceptor [1,2]. The eukaryotic mitochondrial electron transport
system is composed of more than 80 subunits and requires more than
100 additional genes for its assembly [3].
The electron transport system or oxidative phosphorylation
(OXPHOS) system is located within the mitochondrial inner mem-
brane and is the major endogenous source of reactive oxygen species
(ROS) such as superoxide anion (O2•−), hydrogen peroxide (H2O2),tory complex II: Role in cellular
; fax: +81 463 94 8884.
l rights reserved.and hydroxyl radicals (•OH) [4]. Several studies reported that exposing
cells or tissues to hypoxia leads to an increase inmitochondrial ROS pro-
duction, and that it is required for the cellular response to hypoxia
[5–7]. Such endogenously generated molecules can readily attack a
wide variety of cellular entities, resulting in damage that compromises
cell integrity and function [8–10]. This can cause or at least contribute
to a variety of pathologies, including some in humans [10–15]. It has
been estimated that generation of O2•− and its dismutated product
H2O2 through the action of superoxide dismutases (SODs; Cu/Zn-SOD,
Mn-SOD) may constitute as much as 1-2% of total electron ﬂow [16],
although others have placed this value at 0.1% [17].
It is known that oxygen is initially converted to O2•− by electrons
leaked from complexes I and mainly complex III [18–21]. Complex
III generates O2•− by the auto-oxidation of ubisemiquinone (QHo),
formed during the Q cycle [22]. O2•− can be generated at two different
sites, Qo and Q1, within complex III. The Qo site releases O2•− into the
intermembrane space, whereas the Q1 site releases O2•− into the
matrix. Most of the O2•− generated by complex III is generated at the
Qo site [23]. In contrast, O2•− generated by complex I are probably
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I are poorly understood, controversial and dependent on experimental
conditions. Several studies revealed a much higher rate of O2•− produc-
tion during reverse electron transport from succinate to NAD+ than
during forward electron transport [24].
In addition, it is shown that O2•− is also produced from complex II
in Saccharomyces cerevisiae genetic backgrounds that compromise
complex II functionality and from Ascaris suum mitochondrial com-
plex II [25,26]. We have isolated an oxygen hyper-sensitive mutant,
mev-1, from the nematode Caenorhabditis elegans [27]. We have
found that the mev-1 gene was a mitochondrial complex II SDHC
[28] and O2•− is also produced from complex II [29]. We have hypoth-
esized that high succinate concentrations outside the normal physio-
logical range in mitochondrial or cytosolic energy metabolism might
be important for O2•− production during reverse electron transport
under hypoxic conditions [30,31]. In this paper, we review our studies
using animal models, from nematodes to mice, with complex II SDHC
mutations.
2. Lower eukaryote and animal models of mitochondrial complex
II mutations
2.1. C. elegans mev-1 mutant with SDHCG71E mutation
The electron transport system of C. elegans is composed of about
70 nuclear and 12 mitochondrial gene products. It closely parallels
its mammalian counterpart in its metabolism and structure. C. elegans
mitochondrial DNA (mtDNA) is similar in size and gene content to
that of humans [32,33]. The mev-1 mutant was isolated based upon
its hypersensitivity to the ROS-generating chemical methyl viologen
[27]. In addition to its methyl viologen hypersensitivity, mev-1
mutants are oxygen hypersensitive with respect to both development
and aging [27]. The mev-1(kn-1) mutation, which results in an amino
acid substitution at the 71st position from glycine to glutamate
(G71E), has been identiﬁed as residing in the putative gene cyt-1
(a human SDHC gene homologue), which is homologous to the
succinate dehydrogenase (SDH) cytochrome b large subunit in complex
II [28]. The mutation results in a greater than 80% reduction in complex
II activity in themitochondrial membrane fraction. Complex II catalyzes
electron transport from succinate to ubiquinone and contains the citric
cycle enzyme succinate dehydrogenase (SDH), which is composed of
the ﬂavin protein (Fp), the iron-sulfur protein (Ip) and two other
subunits (a small subunit of cytochrome b and a large subunit of
cytochrome b encoded by cyt-1) [34–36]. In vivo, SDH is anchored
to the inner membrane with cytochrome b and is the catalytic com-
ponent of complex II. Using separate assays, it is possible to quantify
speciﬁcally both SDH activity and complex II activity. This was done
with wild type and mev-1 after extracts of each were subjected to
differential centrifugation to separate mitochondria and mitochon-
drial membranes from cytosol [28]. The SDH activity in the mev-1
mitochondrial fraction was experimentally identical to that of wild
type. As expected of a mitochondrial enzyme, no SDH activity was
observed in the cytosol. Thus, the mev-1 mutation affected neither
SDH anchoring to the membrane nor SDH activity per se. However,
it dramatically compromised the ability of complex II to participate
in electron transport. The cytochrome b large subunit is also essential
for electron transport to ubiquinone in complex III. Based upon its
position, the mutation site in mev-1 may affect the domain binding
to ubiquinone.
The mean and maximum life spans of both the wild type andmev-1
mutant were inﬂuenced by oxygen [37]. Wild-type life spans were not
affected by oxygen concentrations between 2 and 40%. On the other
hand, the mean and maximum life spans of the mev-1 mutant under
atmospheric conditions (21% oxygen) were shorter than wild type
[37]. Fluorescentmaterials (lipofuscin) and protein carbonyl derivatives
are formed in vivo as a result of metal-catalyzed oxidation andaccumulate during aging in disparate model systems [38–41]. The
presence of ﬂuorescent materials and protein carbonyl modiﬁcations
can be a speciﬁc indicator of oxidized lipid and protein. The mev-1
mutants accumulated ﬂuorescent materials and protein-carbonyl de-
rivatives at signiﬁcantly higher rates than did their wild-type cohorts
[42,43]. Thus, the aging process in mev-1 animals approximates that of
wild type except for its precocious nature.
The biochemical pathologies of mev-1 include elevated ROS. Spec-
iﬁcity, O2•− levels in both intact mitochondria and sub-mitochondrial
particles are approximately two times greater in mev-1 mutants as
compared to wild type [29]. Given that most O2•− generation is
thought to occur around complex III, this means that themev-1muta-
tion either exacerbates O2•− production at this location or, in some
indirect way, increases O2•− production at another point in electron
transport, perhaps even at complex II. Several experiments suggest
the latter. Another of the biochemical pathologies is that of reduced
glutathione concentration in mev-1 animals [29]. Themev-1mutation
also caused supernumerary embryonic apoptosis especially under
hyperoxia [44]. The abnormal apoptosis was suppressed by mutations
in either ced-3 or ced-4, indicating that the inappropriate signal in
mev-1 embryos stimulated induction of the normal ced-9/ced-3/ced-4
apoptotic pathway in C. elegans [44]. Furthermore, the mev-1;ced-3
double mutant lived longer thanmev-1, which suggests that the super-
numerary apoptosis contributed to the phenotype of life shortening in
mev-1 [44]. In addition, the oxidative stress by hyperoxia inmev-1 ani-
mals rendered them hypermutable to nuclear mutations [45]. Finally, a
number of biochemical pathologies likely derive from the role played by
succinate dehydrogenase in the citric cycle. First, the ratio of lactate to
pyruvate is signiﬁcantly higher in mev-1 mutants, suggesting that a
metabolic imbalance known as lactate acidosis occurs in these animals.
Second, a number of citric cycle intermediates are present at abnormal
concentrations in mev-1mutants. Conversely, ATP levels are normal in
mev-1 mutants. This was initially surprising but may suggest that
mev-1 animals rely more heavily on glycolysis for energy acquisition,
thus explaining the elevated lactate levels. However, it is also possible
that ATP consumption is decreased in mev-1 because of some sort of
global decrease in the metabolic rate that acts to counterbalance the
compromised ATP generation in mev-1 [29]. These results suggest that
age-related complex II deteriorationmight also produce O2•− and conse-
quently accelerate aging.
In a similar fashion, Dr. Lemire and colleagues constructed transgenic
C. elegans strains with a series of mutations in the succinate dehydroge-
nase iron-sulfur subunit (SDHB-1) (a human SDHB homologue). They
also resulted in reduced life spans [46]. These strains are also more
sensitive to oxygen andparaquat (methyl viologen). They overproduced
superoxide anion with decreased succinate–cytochrome c reductase
activity compared to the control strain. Thus, they recapitulate the phe-
notypes of themev-1mutant.
2.2. Drosophila mev-1-mimic and another complex II mutated transgenic
mutants
We investigated the phenotypic effects of mutation in the sdhC gene
(a human SDHC gene homologue) encoding succinate dehydrogenase C
in Drosophila by using transgenic ﬂies expressing a dominant-negative
form, SdhCI71E [47]. Expression of SdhCI71E signiﬁcantly reduced the
mean lifespan by 22% compared to that of control ﬂies [47]. The amount
of protein carbonyl was signiﬁcantly increased, suggesting that a high
level of oxidative stress was induced in these ﬂies with decreasing of
complex II activity [47].
Furthermore, Dr. Benzer and colleagues performed a genetic screen
for mutations that cause decreased survival under hyperoxia (100% O2)
[48]. Among a collection of P-element insertionmutants [49], they iden-
tiﬁed a hyperoxia-sensitive line, EY12081, which has an insertion in the
sdhB gene (a human SDHB gene homologue) encoding the iron-sulfur
protein (Ip, SDHB) as one of mitochondrial complex II subunits. The
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be important for mediating that function [34–36]. Under hyperoxia,
the mean survival time of sdhBEY12081 ﬂies, which have the P-element
insertion site within the 5′ untranslated region (UTR) of the gene
resulting in reducing the expression of sdhB gene, was reduced to 10%
of that of normal ﬂies [48]. Under normoxic conditions, sdhBEY12081
ﬂies displayed a 66% decrease inmean survival time and a 17% decrease
in maximum survival time. There was a 56% decrease in the complex
II-speciﬁc (succinate-dependent/antimycin A-sensitive) respiration
rate, a 40% decrease in the complex II-mediated electron transfer ratio
(malonate-sensitive succinate–cytochrome c reductase activity) and a
32% increase in mitochondrial hydrogen peroxide production, as
compared with wild-type controls [48]. Both mutants (SdhCI71E and
sdhBEY12081 ) mimic the nematode mutants; namely, they are very
similar in complex II mutation-associated ROS production, highly sensi-
tive to oxidative stress, including hyperoxia, and age precociously. The
results from these lower animal models support the consequential
damages of ROS production with electron leakage by mitochondrial
complex II deﬁciency, which ultimately lead to accelerated aging and
age-associated diseases.
3. Human mitochondrial complex II mutations and diseases
In humans, succinate dehydrogenase (SDH) is an enzyme complex
II composed of four subunits encoded by four nuclear genes (SDHA,
SDHB, SDHC and SDHD). SDHC (cybL, 15 kDA, 169 amino acids) and
SDHD (cybS, 12 kDa, 159 amino acids) subunits are hydrophobic
and provide the membrane anchor and binding site for ubiquinone.
SDHA (ﬂavoprotein, 70 kDa, 664 amino acids) and SDHB (iron–
sulphur protein, 27 kDa, 280 amino acids) are probably hydrophilic
with the former involved in substrate binding and oxidation and
the latter in electron transfer [34–36]. The crystal structure of mito-
chondrial respiratory membrane protein complex II has been eluci-
dated in porcines [50]. The SDHB (35.4 kb, 8 exons) and the SDHC
(50.3 kb, 6 exons) genes are located on the short and long arms,
respectively, of chromosome 1 (1p36 and 1q23.3). The SDHD gene
is located on 11q23.1, spans 8.9 kb and contains four exons whilst
SDHA lies on the short arm of chromosome 5 (5p15) and is composed
of 15 exons spread over a genomic region of 38.4 kb. Homozygous
germline mutations affecting the SDHA gene cause Leigh syndrome,
a sub-acute necrotizing encephalomyelopathy during infancy [51,52].
SDHD, SDHB and SDHC heterozygous mutations cause a genetic pre-
disposition to non-chromafﬁn palagamgliomas (PGLs) and adrenal⁄
extra-adrenal pheochromocytomas (PHEOs) [53–55] called ‘PGL/
PHEO syndrome. PGLs are usually benign and slow-growing tumors
of the parasympathetic ganglia with an incidence of roughly
1:30,000–1:100,000 in the general population. They are more fre-
quently located in the head and neck region (HNPGLs) at the carotid
bifurcation (carotid body tumor), along the vagal nerve, in the jug-
ular foramen and in the middle ear space. Following the discovery
of SDHD (OMIM ID: 602690) as the gene responsible for PGL1 in fa-
milial HNPGLs [53], it was subsequently recognized that two other
subunits of this mitochondrial enzyme, SDHC (PGL3, OMIM ID:
602413) and SDHB (PGL4, OMIM ID: 185470) were associated
with heritable PHEO and⁄or PGL [54,55]. SDHB, SDHC and SDHD
gene mutations are responsible for 6% and 9% of sporadic PGLs and
PHEOs, respectively. They also constitute 29% of pediatric cases,
38% of malignant tumors and more than 80% of familial aggregations
of PHEO and PGL [56]. Known risk factors for HNPGLs include condi-
tions associated with chronic hypoxia such as living at a high altitude
and respiratory or heart diseases with chronic arterial hypoxemia. In
fact, Dr. Gimenez-Roqueplo and colleagues studied the biological
effects of a loss-of-function SDHD germline mutation (p.Arg22X)
in an extra-adrenal PGL and a missense SDHB germline mutation
(p.Arg46Gln) in a malignant PHEO with somatic terminal deletion
of 1p [57,58]. In tumor tissues, SDH activitywas abolishedwith increasedexpression of the hypoxia inducible factors (HIF) 1alpha and 2alpha. In
addition, expressionof vascular endothelial growth factors (VEGFs) asso-
ciated with VEGF-R1 and VEGF-R2 were increased in endothelial cells.
This is in agreement with the high vascularization of this endocrine
tumor [57,58]. In addition, the inactivation of SDH activity and succinate
accumulation was shown to inhibit prolyl-hydroxylation of HIF1a and
HIF2a, which is an essential step for its degradation through the complex
VHL-ElonginD-C-Cul2 [59]. We speculate that SDH deﬁciency might
trigger hypoxic conditions, resulting in increased activity of HIFs. Collec-
tively, these alterations may trigger changes in cellular metabolism,
angiogenesis, metastasis and cell proliferation [60].
4. Comparisons of SDHC between prokaryotes, lower eukaryotes,
mouse, pig and human
The amino acid sequences of Escherichia coli K-12 (GenBank ID:
AAA23893.1), C. elegans (GenBank ID: AAA20081.1), Drosophila
melanogaster (fruit ﬂy) (GenBank ID: AAF54602.2), Mus musculus
(house mouse) (GenBank ID: AAH05779.1), Sus scrofa (pig)
(UniProtKB/Swiss-Prot ID: D0VWV4.2) and Homo sapiens (human)
(GenBank ID: AAC27993.1) for the gene named succinate dehydroge-
nase C (SdhC), cytochrome b large (CybL), CYT-1 or SDHC subunit
were retrieved fromEntrezNucleotide of National Center for Biotechnol-
ogy Information (NCBI) (http://www.ncbi.nlm.nih.gov/protein). These
amino acid sequences can be analyzed by the multiple sequence align-
ment tools of ClustalW [61], which is one of several mainstream,
public-access sequence analysis applications provided by the European
Bioinformatics Institute (EMBL-EBI) (Fig. 1) [62]. The sequence analysis
can be also performed by InterProScan, which was created to unite
secondary databases that contain overlapping information on protein
families, domains and functional sites [63]. InterProScan is also provided
by the European Bioinformatics Institute (EMBL-EBI). Consensus pat-
terns in the PROSITE database [64]: R–P–[LIVMT]–x(3)–[LIVM]–x(6)–
[LIVMWPK]–x(4)–S–x(2)–H–R–x–[ST], which is a putative a heme
ligand “succinate dehydrogenase cytochrome b subunit signature 1”
(IPR018495, SDH_CYT_1, PS01000) and H–x(3)–[GA]–[LIVMT]–R–[HF]–
[LIVMF]–x–[FYWM]–D–x–[GVA], which is a putative heme ligand “succi-
nate dehydrogenase cytochrome b subunit signature 2” (IPR018495,
SDH_CYT_2, PS01001) are highly conserved among animals (Fig. 2)
[65–76]. The SDH_CYT_1 domain sequence is positively related to the ac-
tivity of succinate–ubiquinone oxidoreductase as a ubiquinone-binding
site [68,69,72–76].
In the C. elegans mev-1 mutant, the mutational site which has been
located in glycine at 71st amino acid position in the ubiquinone-
binding region between succinate–ubiquinone oxidoreductase activity
region is maintained at the neutral and hydrophobic amino acid resi-
dues between Drosophila (Isoleucine at the 71st amino acid position:
I71), pig and human (Isoleucine at the 69th amino acid position: I69)
and mouse (Valine at the 69th amino acid position: V69). Therefore, it
was anticipated that this mutation, whichwas converted from a neutral
to an acidic amino acid, could be applied to higher mammals for use as
models to study aging and age-associated diseases that are triggered by
oxidative stress.
In humans, it was reported that the SDHC gene mutation caused
paraganglioma type 3 (PGL3) [54]. Since that time, several type muta-
tions of SDHC have been found in paragangliomas, pheochromocyto-
mas and gastrointestinal stromas (Table 1). Most of the SDHC gene
mutations resulting in amino acid missense, ﬂame shift, nonsense or
deletion mutations destroy or delete the quinone-binding site (from
50 to 74 amino acid sequence) or heme-binding site (from 127 to
140 amino acid sequence) in the succinate–ubiquinone oxidoreduc-
tase main activity region (Table 1). However, there are some muta-
tions in the N terminal region from the 1st to 41st amino acids that
are not in E. coli, so the structure and function have not been become
clear in mammals (Fig. 1). Using the multiple sequence alignment
tool ClustalW, a new predicted quinone or heme binding amino acid
Homo sapiens (human) 
Sus scrofa (pig) 
Mus muscles (mouse) 
Drosophila melanogaster (fruit fly) 
Caenorhabditis elegans (worm) 
Escherichia coli K-12 (bacterium) 
Fig. 1. The alignment between SDHC amino acid sequences of Escherichia coli K-12, Caenorhabditis elegans, Drosophila melanogaster, Mus muscles, Sus scrofa and Homo sapiens. Red
color and blue color indicate the SDH_CYT_1 domain and SDH_CYT_2 domain regions. Asterisk (*) indicates positions which have a single, fully conserved residue. Colon (:) indi-
cates conservation between groups of strongly similar properties — scoring>0.5 in the Gonnet PAM 250 matrix. Period (.) indicates conservation between groups of weakly similar
properties — scoring=b0.5 in the Gonnet PAM 250 matrix.
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nate hehydrogtenase cytochrome b subunit signature 1” (IPR018495,
SDH_CYT_1, PS01000) (R–P–[LIVMT]–x(3)–[LIVM]–x(6)–[LIVMWPK]–
x(4)–S–x(2)–H–R–x–[ST]), can be found from the 5th to 30th amino
acids in the N terminal region of SDHC (Fig. 2). The sequence contains
some well-known heme-binding motifs, including nucleophilic amino
acids such as cysteine, histidine and serine, basic amino acids and
hydrophobic amino acids. Therefore, we expected that the mutations
in the N terminal region of SDHC should also result in tumorigenesis
which causes paragangliomas, pheochromocytes and gastrointestinal
stromas.
Based upon these ﬁndings, we anticipated that the C. elegans
mev-1-type mutation, which resulted in the missense amino acidHomo sapiens (human)
Mus muscles (mouse)
SDH_CYT_1 (reverse)
Homo sapiens (human)
Mus muscles (mouse)
Homo sapiens (human)
SDH_CYT_1 (reverse)
Mus muscles (mouse)
SDH_CYT_1 (reverse)
Fig. 2. The alignments between SDHC N-terminal regions of Mus muscles and Homo sapience
cate the nucleophilic amino acids, nucleophilic basic amino acids and basic amino acids. As
dicates conservation between groups of strongly similar properties — scoring>0.5 in the
similar properties — scoring=b0.5 in the Gonnet PAM 250 matrix.mutation to glutamate, could be useful in clarifying not only the ef-
fects of oxidative stress on aging but also tumorigenesis and other
age-related pathologies in mouse models.
5. Mouse embryonic ﬁbroblast cells with SDHCV69E mutation
We established a transgenic mouse embryonic ﬁbroblast NIH3T3
cell line with the equivalent mutation (V69E) in SDHC as C. elegans
mev-1 [77]. The mutation corresponds to the amino acid substitution
of glutamic acid from glycine at position 71 (G71E) in the C. elegans
mev-1 mutant allele kn1 [28]. It is thought that the serine, histidine
and cysteine residues, which are located in the closed mutation site
within the ubiquinone binding region, constitute an active center of, and reverse SDH_CYT_1 domain sequence. Red color, green color and blue color indi-
terisk (*) indicates positions which have a single, fully conserved residue. Colon (:) in-
Gonnet PAM 250 matrix. Period (.) indicates conservation between groups of weakly
Table 1
Cases of SDHC gene mutations in human diseases.
Case
reports
Exon Mutation
(nucleotide)
Mutation
(codon and amino acid)
Source
1 1 3G>A M1I/ loss of the start
codon/ M38 available
for new start codon/
exon 1 and 2 deletion
Niemann S. et al.
[54], Science
(2000)
2 Intron
5
IVS5+1G>T Exon 5 skipping deletion/
reading-frame shift of
exon 6/ heme binding
site deletion
Niemann S. et al.
[100], Hum Genet
(2003)
3 6 473T>C L158P/ exon 6 terminal
deletion
Bauters C. et al.
[101], J Med
Genet (2003)
4 6 8372 bp
deletion
Exon 6 deletion/ heme
binding site deletion
Baysal B.E. et al.
[102], J Med
Genet (2004)
5 1 1A>G M1V/ similar to case
report #1
Schiavi F. et al.
[103], JAMA
(2005)
2 39C>A C13X/ exon 2 terminal
deletion
4* 214C>T R72C/ quinone binding
site mutation
* Bayley J.P. et al.
[104], BMC Med
Genet (2006)
6 439C>T Q147X/ exon 6 terminal
deletion
6 3 126 G/A W42X/ exon 3 terminal
deletion
Mannelli M. et al.
[105], J Med
Genet (2007)
7 Intron
5
IVS5+1G>A Similar to case report #2 McWhinney S.R.
et al. [106],
N Engl J Med
(2007)
2 43C>T R15X/ exon 2 terminal
deletion
8 5 397C>T R133X/ exon 6 deletion/
heme binding site
deletion
Zbuk K.M. et al.
[107], Nat Clin
Pract Oncol
(2007)
9 Intron
2
78-2A>G Exon 3 skipping deletion Peczkowska M.
et al. [108],
Nat Clin Pract
Endocrinol Metab
(2008)
592 T. Ishii et al. / Biochimica et Biophysica Acta 1827 (2013) 588–597oxidoreductase and acts as nucleophilic amino acid. The mutation
probably results in an excess electron leakage from electron transport
by decreasing the afﬁnity between complex II and ubiquinone and
thereby uncouples electron transfer. This alternation would be pre-
dicted to reduce complex II-III activity.
The mutation at the 69th position, changing a neutral amino acid
(valine) to an acidic amino acid (glutamate) in mouse SDHC, is located
within the functional ubiquinone-binding region of complex II [77].
After transfection, we selected SDHC E69 cell lines as mev-1 cells that
expressed equal amounts of sdhcmRNA from the transgene and endog-
enouswild-type allele [77]. Overexpressed transgene cell lineswere not
obtained, most likely because cells with more than 80% abnormalmito-
chondrial DNA are inviable [78]. Consistent with this prediction, RNAi
with cyt-1 produced an embryonic lethal in C. elegans [79].
O2•− production was slightly but not statistically signiﬁcantly
higher in untreated mitochondria isolated frommev-1 cells. The addi-
tion of succinate (a substrate for complex II that stimulates complex II
activity) resulted in a large increase in O2•− production in mitochon-
dria isolated from the mev-1 cells. The enzymatic activity of complex
II in the mev-1 cells was reduced to 40% whereas the activity of com-
plex I was unaffected [77]. ATP levels were not affected, suggesting
that this mutation did not directly compromise cell survival through
reduced respiration per se. Under these conditions, O2•− levels were
signiﬁcantly higher in intact mitochondria isolated from mev-1 cells
at both one month and three months after establishment [77].
The mev-1 cells accumulated cytoplasmic carbonyl proteins, a
marker of oxidative stress, at a faster rate than wild type. In addition,the amount of 8-hydroxydeoxyguanosine (8-OHdG), a DNAmarker of
oxidative stress was two-fold higher in mev-1 cells [77]. During
the time necessary for colony formation on the medium plates,
wild-type NIH3T3 cells maintained normal ﬁbroblast morphology
and grew in a monolayer. Conversely, the mev-1 cells showed a loss
of contact inhibition and had many apoptotic molecule-like granules
during the ﬁrst month after establishment [77]. During the period of
colony formation, some clefts characteristic of cell death were found
in the center of some colonies. Consistent with this, the activity of
the apoptosis marker caspase 3 was 1.3 to 1.8 times higher in mev-1
cells [77]. In three-month mev-1 cells, the morphology was changed
from the typical solid and elongated ﬁbroblasts to smooth and round-
ed cells. In addition, the mev-1 cells formed multiple layers. The dou-
bling time of one-month mev-1 cells after establishment was 1.5 to 2
times slower than that of wild-type cells; however, in three-month
mev-1 cells the doubling time was completely recovered to that of
wild type [77].
When one-month mev-1 cells were injected under the epithelium
of nude mice, they rapidly disappeared as compared to wild type. This
suggests that these cells were dying of apoptosis and were phagocy-
tized shortly after injection. Conversely, injecting the same number
of three-month mev-1 cells resulted in the production of tumors
[77,80]. The transformation rate on soft-agar medium for wild-type
NIH3T3 cells was less than 1×10−6. On the other hand, the rates
were 5×10−4 for the one-month mev-1 cells and 5×10−3 for the
three-month cells [77]. Thus, the mev-1 cells had 100- to 1,000-fold
higher transformation rates than wild-type cells. The 6-thioguanine
tolerance test was performed as an indicator of mutations in the
hprt gene on nuclear DNA [77]. The three-monthmev-1 cells were ap-
proximately twice as resistant as the one-month and wild-type cells,
indicating thatmev-1 cells are hypermutable with excessive apoptotic
cell death [77]. In the transformed three-month mev-1 cells, benign
tumor's characterizations were conﬁrmed under the epithelium of
nude mice [80]. Interestingly, the cells maintained active caspase 3
through caspase 8 and 9 with cytochrome c release from mitochon-
dria and p53 and p21 activation [80]. On the other hand, cell prolifer-
ation was activated by AP-1 transcriptional activation through Ras–
Raf and Ras–MEKK signal transductions [80]. Therefore, we anticipate
that the mev-1-like cell lines are suitable models to clarify the molec-
ular mechanisms of cell senescence and tumorigenesis and the path-
ogenesis of paragangliomas, pheochromocytes and gastrointestinal
stromas in humans (Fig. 3).
6. Tet-mev-1 conditional transgenic mice with SDHCV69E mutation
6.1. Establishment ofmev-1-mimic (Tet-mev-1) conditional transgenic mice
A mev-1 transgenic mouse was created that contained the mutated
SDHCV69E transgene (unpublished data). This mouse had increased
O2•− levels in the mitochondria of its heart and muscle as well as
decreased body weight and locomotion activity. Abnormal mitochon-
drial structures were observed, especially in muscles. These mani-
fested themselves as swelling and enlargement, which resulted in
muscle-ﬁber atrophy. Unfortunately, this mev-1 transgenic mouse
was infertile, which prevented propagation of the strain for further
studies. Additional conditional transgenic mice that ubiquitously in-
duce the mutated SDHCV69E over-expression are extremely likely to
meet with a similar fate, signiﬁcantly limiting their utility. In order
to overcome this limitation we established amev-1 conditional trans-
genic mouse that does not constitutively overexpress the mutated
SDHCV69E encoding SDHC transgene [81]. We contemplated develop-
ing anothermev-1model mouse using a knock-in approach. However,
it has been reported that most of hereditary diseases and genetic disor-
ders have been impacted by genomic imprinting [82,83]. Therefore, it
was feared that the individual phenotypes could be unstable in the
same strain, even though it has been unclear whether the imprinting
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a modiﬁed tetracycline system (Tet-On/Off system) to construct a
mev-1-mimic mouse model.
The Tet-On/Off system allows for the induction and repression of
transgenes in which expression is reversibly controlled by the presence
of the antibiotic tetracycline [or more commonly the tetracycline-
derivative doxycycline (Dox)]. As developed by Bujard and coworkers
[84], the original system employed a tetracycline transactivator
(tTA) protein that was created by fusing two proteins (TetR from
E. coli and VP16 from Herpes Simplex Virus). The original Tet-On/Off
system was modiﬁed using the reverse Tc-controlled transactivator
(rtTA) [85] and the Tc-controlled transcriptional silencer (tTS) withthe improved Kruppel-associated box (KRAB) domain of human
Kox-1 [86,87] that also included a nuclear localization signal
(nls). In this system, the tTS binds to the Tc-responsive element
(tetracycline-responsive element: TRE) in the absence of Dox, leading to
the repression of leaky activation of TRE-mediated transcription caused
by weak binding of rtTA to TRE. As the result of these modiﬁcations,
our modiﬁed Tet-On/Off system enables the transgene to be expressed
at lower levels such that theymore reasonably approximate endogenous
expression of the transgene. This was ultimately engineered into a single
plasmid vector rather than the three-plasmid system typical of
Tet-On/Off systems [81]. It is also not leaky in the absence of the inducer
Dox, which can be problematic at times.
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mev-1 model systems, and the various consequences of excess ROS on a variety of phenomena that relate to aging.
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The fourteen lines of mev-1-mimic (Tet-mev-1) conditional trans-
genic mice with SDHCV69E mutation were established using our modi-
ﬁed Tet-On/Off construct [81]. As was the case with C. elegans mev-1
and mice embryonic ﬁbroblast mev-1 cells, these mice were all hyper-
sensitive to methyl viologen, which induces oxidative stress [81]. In
newborn Tet-mev-1 mice that had been exposed continuously to Dox
from the embryonic stage onward resulting in the low-birth-weight in-
fants, O2•− levels were increased compared to those of wild-type mice
treated with Dox [81]. Carbonylated proteins accumulated to higher
levels in the intracellular membrane fraction protein of newborn
Tet-mev-1 mice that were exposed to Dox. Moreover, both TUNEL-
stained and c-Caspase-3 immunostained brown cells, which are
markers of programmed cell death, were observed more frequently in
Tet-mev-1 mice than in the wild-type controls. This included brain,
lung, liver, kidney (especially in the adrenal region), salivary grand,
nasal sinus tissue (especially secretory cells and mucosal cells) and
muscles [81]. Interestingly, these programed cell deaths were observed
in the stomach, intestine, spleen and lymphatic tissues of wild-type
C57BL/6j mice with Dox and Tet-mev-1 mice with Dox at roughly
equal rates. Thus, the increased mitochondrial oxidative stress that led
to excessive apoptosis resulted in a signiﬁcant decrease in body size
and weight between the developmental stages leading to the growth
retardation in Tet-mev-1 mice, just as in the C. elegans mev-1 mutant
[81]. In Tet-mev-1 treated with Dox, the electron transport ratio from
complex II to III through ubiquinone was decreased as compared to
thewild-type C57BL/6j treatedwithDox. Surprisingly, therewas no sig-
niﬁcant difference in the reduced cytochrome c levels dependent on
succinate–ubiquinone oxidoreductase activity as was the case with
malonate-sensitive succinate–cytochrome c reductase activity [81].We have considered that the methodology may be not be sufﬁciently
optimized to analyze the activity in lysed samples of developmental
stage tissues.
These phenomena, including decreasing electron transport ratio,
increase in O2•− production and accumulation levels, excessive apo-
ptosis, low-birth-weight infants and growth retardation in Tet-mev-1
mice, were recovered by CoQ-H2 supplementation to that of the
wild-type C57BL/6j [81]. This suggests that the electron leakage led
to O2•− overproduction from mitochondria with excessive apoptosis.
In turn, these biochemical defects resulted in the low-birth-weight
infant and growth retardation during the embryonic and neonatal
periods, which was caused by a decrease in the afﬁnity of ubiquinone
for complex II with mutated SDHCV69E.
6.3. Phenotypes in the matured tissue “cornea” after development
We have determined the tissue functional changes in response to
mitochondrial oxidative stress in C57BL/6j mice [88]. We determined
that the oculus was more sensitive to mitochondrial oxidative stress
with age compared to other tissues. Therefore, we expected that the
oculus, which has contact with atmosphere, acutely manifested the
oxidative stress-induced mev-1-mimic phenotypes. In fact, a prepon-
derance of cataracts was demonstrated in mev-1 transgenic mouse
(unpublished data).
In the eyes of Tet-mev-1 conditional transgenicmouse, complex II-III
activity was decreased. This was likely caused by the electron leakage
between complex II and ubiquinone when the mutant SDHCV69E was
induced by doxycycline treatment [89]. This led to increased levels of
carbonylated protein and 8-OHdG nucleotide levels with increasing
mitochondrial superoxide anion (O2•−) production in the eyes, particu-
larly as Tet-mev-1 mice grew older. In the corneal epithelium of
Table 2
Functional changes of mev-1 models with SDHC mutation.
Functional changes References
Mitochondrial structural abnormalities
Disappearance of cristae Senoo-Matsuda N. et al. [44], J Biol
Chem (2003)
Swellings and enlargements Ishii T. et al. [77], Cancer Res (2005)
Energy metabolisms and respiratory chain dysfunctions
Hypersensitivity to oxygen Ishii N. et al. [27], Mutat Res (1990)
Decreasing succinate-CoQ
oxidoreductase activities
Ishii N. et al. [28], Nature (1998)
Increasing superoxide anion
production
Senoo-Matsuda N. et al. [29], J Biol
Chem (2001)
Decreasing mitochondrial
membrane potential
Senoo-Matsuda N. et al. [44], J Biol
Chem (2003)
Lactic acidosis Ishii T. et al. [77], Cancer Res (2005)
Tsuda M. et al. [47], Biochem
Biophys Res Commun (2007)
Ishii T. et al. [81], Mitochondrion (2011)
Onouchi H. et al. [89], Invest Ophthalmol
Vis Sci. (2012)
Oxidative stress to cellular components
Increasing lypofuscin, carbonylated
proteins and 8-OHdG
Hosokawa H. et al. [42], Mech. Ageing
Dev.(1994)
Nuclear hypermutability Adachi H. et al. [43], J. Gerontol.
Ser. A Biol. Sci. Med. Sci. (1998)
Hartman P. et al. [45],
Mech. Ageing Dev. (2004)
I shii T. et al. [77], Cancer Res (2005)
Tsuda M. et al. [47], Biochem Biophys
Res Commun (2007)
Ishii T. et al. [81], Mitochondrion (2011)
Onouchi H. et al. [89], Invest Ophthalmol
Vis Sci. (2012)
Decreasing antioxidant activities
Decreasing superoxide dismutase
(SODs) levels
Senoo-Matsuda N. et al. [29], J Biol
Chem (2001)
Decreasing glutathione levels Yasase S. et al. [109], Mech. Ageing
Dev. (2002)
Alterations cellular and organismal processes
Premature aging Ishii N. et al. [27], Mutat Res (1990)
Excessive apoptosis Ishii N. et al. [28], Nature (1998)
High-transformation rate Senoo-Matsuda N. et al. [44], J Biol
Chem (2003)
Cell cycle arrest Ishii N. et al. [110], Mech. Ageing
Dev. (2004)
Accelerated aging Ishii T. et al. [77], Cancer Res (2005)
Tsuda M. et al. [47], Biochem Biophys
Res Commun (2007)
Miyazawa M. et al. [80], BioScience
Trends (2008)
Onouchi H. et al. [89], Invest Ophthalmol
Vis Sci. (2012)
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resulting in delayed epithelializationwith keratitis relative to wild-type
C57BL/6j mice, particularly as animals aged [89]. It has been reported
that keratitis and delayed epithelialization might be caused by hyper-
glycemia and high oxidative stress conditions [90]. In the corneal endo-
thelium of Tet-mev-1 mice, it was conﬁrmed that the age-dependent
decrease in cell number was accelerated compared to wild-type
C57BL/6j mice [89]. Interestingly, the thickened Descemet's membrane
with age was present in Tet-mev-1mice relative to wild-type C57BL/6j
mice. Both the decrease of corneal endothelial cells and the increase
in thickness of Descemet's membrane in Tet-mev-1mice are consistent
with the pathological phenotypes of Fuchs' corneal dystrophy (FCD)
[91]. Finally, corneas were thinner, primarily owing to decreased num-
bers of corneal stromal cells as the Tet-mev-1 animals aged. As well,
increased catalase activity in Tet-mev-1 mice was noted compared
with wild-type C57BL/6j mice [89]. It has been reported that the cata-
lase activity is increased in human keratoconus [92]. Our results suggest
that the pathogenesis of keratoconus was due to corneal thinning with
decreasing number of corneal stromal cells caused by excessive mito-
chondrial oxidative stress with increasing catalase activity.
To summarize, we have demonstrated accelerated age-dependent
corneal pathophysiological changes in a Tet-mev-1 mouse model with
excessive mitochondrial oxidative stress. This includes delayed epithe-
lialization with keratitis, decreasing endothelial cell number, thickened
Descemet's membrane and corneal stromal thinning. Therefore, we
anticipate that the pathogenesis andmolecular mechanisms of FCD, de-
layed epithelializationwith keratitis and keratoconus can be clariﬁed by
future analyses of Tet-mev-1 mice with mitochondrial oxidative stress.
In recent years, ROS have been increasingly implicated as a causative
factor triggering eyes disease; however, a speciﬁc role and molecular
mechanisms bywhich ROS effect ocular dysfunctions (dry eyes, glauco-
ma and age-related macular degeneration etc.) remain elusive [93–95].
In the future, we anticipate that these pathologies might be clariﬁed by
analyses of Tet-mev-1mice.
7. Future directions
Chronic elevation in ROS levels presumably results in damage to the
various components of the electron transport system, which in turn re-
sults in the production of ROS at an even higher rate. The net result of
this cascade is cellular and organismal aging (Figs. 3 and 4). Oberley
and colleagues argued for the importance of O2•− in cancer, differentia-
tion and aging [96–98]. Our data imply that a mutation in the mev-1
(corresponding to cyt-1 or SDHC) gene of both C. elegans and mouse
cells leads to apoptosis and high mutation frequency in the nuclear
genome, most likely because mitochondrial abnormalities lead to ex-
cess ROS production in mitochondria. Mitochondrially derived ROS
can mutate other genes, including tumor suppressor genes and onco-
genes and can lead to cellular transformation. Indeed, a signiﬁcant
fraction of the mev-1 cells that survived apoptosis were transformed.
These data support the notion that oxidative stress from mitochondria
play an important effect on both apoptosis, which leads to precocious
aging and tumorigenesis (Table 2; Figs. 3 and 4).
A mutation in SDHB, SDHC or SDHD of complex II was found in pa-
tients of PGL/PHEO syndromes [53–58]. It is still unclearwhether oxida-
tive stress contributes to the symptoms of these diseases, but in general,
inhibition of electron ﬂow causes electron leakage from the complexes
and consequently increases ROS production. It has been hypothesized
that reverse electron transport under hypoxic conditions or excessive
succinate overload causes the ROS production leading to a series of
hypoxic responses that include transcriptional alterations leading to
changes in cellularmetabolism, angiogenesis, metastasis and cell prolif-
eration that could result in tumorigenesis [59,60,99] (Fig. 3).
In addition, it is well known that oxidative stress with mitochon-
drial dysfunctions can result in the breakdown of homeostasis func-
tions and tissue networks leading to hyperglycemia and chronicinﬂammation. These can contribute to neurodegenerative diseases, car-
diovascular diseases and diabetes [12–15] (Fig. 4). Thus, we anticipate
that the mev-1 models cause an electron leakage resulting in O2•− pro-
duction between complex II and ubiquinone. As such, the Tet-mev-1
mice with SDHCV69E mutation will be especially suitable for not only
for the study of tumorigenesis and carcinogenesis such as PGL/PHEO
syndromes, but also some age-related disease models. These would
include chronic inﬂammation-related diseases or lifestyle-related dis-
eases such as cardiovascular disease and diabetes as well as excessive
apoptosis-related diseases; that is, neurodegenerative diseases such as
Alzheimer's disease and Parkinson's disease (Fig. 4).
We have recently analyzed a variety of additional Tet-mev-1
mouse phenotypes. The data would suggest that thesemev-1 animals
596 T. Ishii et al. / Biochimica et Biophysica Acta 1827 (2013) 588–597will continue to serve as a valuable whole-animal model for the ef-
fects of mitochondrial oxidative stress (Fig. 4).
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